论文部分内容阅读
目的:观察唑来膦酸联合化疗治疗肺癌骨转移疼痛患者的临床效果。方法:选取2013年06月-2015年02月重庆市垫江县人民医院收治的肺癌骨转移疼痛患者60例,按随机数字表法将其分成实验组与对照组,每组各30例,对照组单纯应用化疗方案治疗,实验组在化疗的基础上应用唑来膦酸治疗,比较两组骨转移疼痛治疗效果。结果:实验组镇痛起效时间为(2.23±0.03)d,短于对照组的(20.33±2.21)d,组间比较,差异有统计学意义(P<0.05);实验组骨转移疼痛治疗有效率为90.0%,显著高于对照组的43.3%,差异有统计学意义(P<0.05)。结论:唑来膦酸联合化疗治疗肺癌骨转移疼痛,疗效满意,且不增加患者不良反应。
Objective: To observe the clinical effect of zoledronic acid combined with chemotherapy in patients with bone metastasis of lung cancer. Methods: Sixty patients with bone metastasis of lung cancer who were treated in Dianjiang County People’s Hospital of Chongqing from June 2013 to February 2015 were selected and divided into experimental group and control group according to random number table method, with 30 cases in each group. Groups were treated with chemotherapy alone. The experimental group was treated with zoledronic acid on the basis of chemotherapy, and the treatment effect of bone metastases was compared between the two groups. Results: The onset time of analgesia in experimental group was (2.23 ± 0.03) d, which was shorter than that in control group (20.33 ± 2.21) d, the difference was statistically significant (P <0.05) The effective rate was 90.0%, significantly higher than 43.3% of the control group, the difference was statistically significant (P <0.05). Conclusion: Zoledronic acid combined with chemotherapy for the treatment of bone metastases of lung cancer has satisfactory curative effect and does not increase adverse reactions in patients.